Here’s What Excited Hedge Funds Have To Say About AbbVie Inc (ABBV)

Page 2 of 2

The rout in the stock market during August led AbbVie Inc (NYSE:ABBV) down to the point that it’s currently being traded at an earnings multiple of 11.83. Robbins’ line of reasoning would suggest that the company is being sold at an even more attractive valuation now. Also, as far as Humira is concerned, which is a therapy based on proteins using genetic engineering for treating various kinds of arthritis and also Crohn’s disease, it received FDA approval for the treatment of acne inversa with a seven-year period of market exclusivity in the U.S. for the disease. So, there is hope of exclusive revenues at least in some areas for treatment even after 2017, but at the same time the significance of Humira for AbbVie Inc (NYSE:ABBV) can’t be ignored. For the second quarter ending in June, Humira contributed more than 60% to the company’s top line.

Disclosure: None

Page 2 of 2